
BEIJING, Jan. 1 (Xinhua) -- China's new national medical insurance catalog came into effect Wednesday, including 70 new drugs with their prices slashed by 60.7 percent on average.
Eight domestically-produced drugs that are seen as "major innovations" and have just hit the market in recent years are among the new additions, according to the National Healthcare Security Administration (NHSA).
Some 22 anti-cancer drugs, seven drugs for rare diseases, 14 for chronic diseases and four for children will be included in the catalog, and the prices of three new drugs for hepatitis C will be reduced by an average of 85 percent, said the NHSA.
Most of the additions are new drugs of high clinical value that can be used to treat multiple diseases including cancer, diabetes and tuberculosis, and the prices of most imported drugs will be set at the lowest in the world.
After the price reduction and medical insurance reimbursements, the financial burden on patients will be eased by over 80 percent.
The additions are part of the first adjustments to the catalog since the NHSA was established in 2018. After the adjustments, the 2019 catalog has a total of 2,709 drugs, compared with 2,645 in 2017.
Fire brigade in Shanghai holds group wedding
Tourists enjoy ice sculptures in Datan Town, north China
Sunset scenery of Dayan Pagoda in Xi'an
Tourists have fun at scenic spot in Nanlong Town, NW China
Harbin attracts tourists by making best use of ice in winter
In pics: FIS Alpine Ski Women's World Cup Slalom
Black-necked cranes rest at reservoir in Lhunzhub County, Lhasa
China's FAST telescope will be available to foreign scientists in April
"She power" plays indispensable role in poverty alleviation
Top 10 world news events of People's Daily in 2020
Top 10 China news events of People's Daily in 2020
Top 10 media buzzwords of 2020
Year-ender:10 major tourism stories of 2020
No interference in Venezuelan issues
Biz prepares for trade spat
Broadcasting Continent
Australia wins Chinese CEOs as US loses